The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
The National Institute for Health and Care Excellence (NICE) has recommended amivantamab (Rybrevant) plus lazertinib ...
The APPLE trial began recruitment in November 2017 and ended in February 2020 (5). It was a randomised, open-label, non-comparative, multicentre, phase II study which enrolled treatment naïve patients ...
Merus has reported a 79% 12-month survival rate in cancer patients on its bispecific antibody, cementing William Blair analysts' belief the candidate has a “best-in-disease profile.” The bispecific ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback